Table 4.
Hazard ratios (95% confidence interval) of incident ischemic stroke associated with number of sites with valvular calcification progression, MESA, 2000–2016
| Number of left valve sites with progression of calcification | Total / p-for-trend | |||
|---|---|---|---|---|
| No progression | One site only (AVC or MAC) | Both sites (AVC and MAC) | ||
| N (row %) | 4537 (82.6%) | 814 (14.8%) | 144 (2.6%) | 5495 |
| Ischemic stroke; n (%) | 116 (2.6%) | 41 (5.0%) | 10 (6.9%) | 167 (3.0%) |
| Person-years | 52533 | 8235 | 1381 | 62149 |
| Incidence rate a (95% CI) | 2.21 (1.84 – 2.65) | 4.98 (3.67 – 6.76) | 7.24 (3.90 – 13.46) | 2.69 (2.31 – 3.13) |
| Model 1 | 1 (reference) | 1.50 (1.03 – 2.17) | 1.72 (0.88 – 3.35) | 0.02 |
| Model 2 | 1 (reference) | 1.45 (1.00 – 2.11) | 1.74 (0.89 – 3.41) | 0.02 |
| Model 3 | 1 (reference) | 1.34 (0.92 – 1.96) | 1.60 (0.82 – 3.13) | 0.06 |
| Model 4 | 1 (reference) | 1.26 (0.86 – 1.84) | 1.46 (0.74 – 2.87) | 0.14 |
AVC= aortic valve calcium; MAC= mitral annular calcium
Fonts in bold are statistically significant, p<0.05.
Incidence rate is unadjusted and per 1,000 person-years
Model 1: age, race/ethnicity, sex, MESA site, CT scanner type, and time between baseline and follow-up CT.
Model 2: Model 1+ educational status, BMI, smoking status, pack-years of smoking, and physical activity.
Model 3: Model 2 + systolic blood pressure, diastolic blood pressure, use of antihypertensives, use of lipid lowering medications, total cholesterol, HDL-cholesterol, LDL-cholesterol, diabetes status and eGFR.
Model 4: Model 3 + baseline coronary calcium.